Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)

References

• Savage KJ, Chhanbhai M, Gascoyne RD, et al. Characterization of peripheral T cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 2004;15:1467–1475.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.
   Google Scholar
• Armitage JO. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012;87:511–519.
   PubMed Web of Science ®Google Scholar
• Bertolini F, Paolucci M, Peccatori F, et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Haematol 1999;106:504–509.
   PubMed Web of Science ®Google Scholar
• Salven P, Orpana A, Teerenhovi L, et al. Simultaneous elevation in the serum concentration of the angiogenic growth factors and bFGF is an independent predictor of poor prognosis in patients with non-Hodgkin's lymphoma: a single institution study of 200 patients. Blood 2000;96:3712–3718.
   PubMed Web of Science ®Google Scholar
• Gratzinger D, Zhao S, Tibshirani RJ, et al. Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest 2008;88:38–47.
   PubMed Web of Science ®Google Scholar
• Rafii S, Lyden D, Benezra R, et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?Nat Rev Cancer 2002;2:826–835.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68–74
   PubMed Web of Science ®Google Scholar
• Kuramoto K, Sakai A, Shigemasa K, et al. High expression of MCL1 gene related to vascular endothelial growth factor is associated with poor outcome in non-Hodgkin's lymphoma. Br J Haematol 2002;116:158–161.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al.; Lymphoma/Leukemia Molecular Profiling Project. Stromal gene signatures in B cell lymphomas. N Engl J Med 2008;359:2313–2323.
   PubMed Web of Science ®Google Scholar
• Zhao WL, Mourah S, Mounier N, et al. Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cell in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. Lab Invest 2004;84:1512–1519.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang L, Zhou D, et al. Expression of tumor-associated macrophages and vascular endothelial growth factor correlates with poor prognosis of peripheral T-cell lymphoma, not otherwise specified. Leuk Lymphoma 2011;52:46–52.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizmab plus irinotecan, fluoracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–2342.
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Palitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542–2550.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
   Web of Science ®Google Scholar
• Advani RH, Hong F, Horning SJ, et al. Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial. Leuk Lymphoma 2012;53:718–720.
   PubMed Web of Science ®Google Scholar
• de Leval L, Rickman DS, Thielen C, et al. The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. Blood 2007;109:4952–4963.
   PubMed Web of Science ®Google Scholar
• Ganjoo KN, An CS, Robertson MJ, et al. Rituximab, bevacizumab and CHOP (RE-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma 2006;47:998–1005.
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Unger JM, Rimsza LM, et al. A phase II trial of standard dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood 2012;120:1210–1217.
   PubMed Web of Science ®Google Scholar
• Seymour JF, Pfreundshuh M, Coiffier B, et al. The addition of bevacizumab to standard therapy with R-CHOP in patients with previously untreated diffuse large B-cell lymphoma is associated with an increased rate of cardiac adverse events: final analysis of safety and efficacy outcomes from the placebo-controlled phase 3 MAIN study. Blood 2012;120(Suppl. 1): Abstract 58.
   Web of Science ®Google Scholar
• AbouYabis AN, Shenoy PJ, Sinha R, et al. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma. ISRN Hematol 2011;2011: 623924.
   PubMedGoogle Scholar
• Schmitz N, Trumper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116:3418–3425.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Hayama M, Yoshino T, et al. Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers. Br J Haematol 2010;153:582–588.
   Web of Science ®Google Scholar
• Stewart M, Talks K, Leek R, et al. Expression of angiogenic factors and hypoxia inducible factors HIF 1, HIF 2 and CA IX in non-Hodgkin's lymphoma. Histopathology 2002;40:253–260.
   PubMed Web of Science ®Google Scholar
• Reimer P, Rudiger T, Geissinger E, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009;27: 106–113.
   PubMed Web of Science ®Google Scholar
• d’Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012;30:3093–3099.
   PubMed Web of Science ®Google Scholar
• Mahadevan D, Unger JM, Spier CM, et al. Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma. Cancer 2013;119:371–379.
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Pro B, Pinter-Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol 2011;29:1182–1189.
   PubMed Web of Science ®Google Scholar
• Coiffier C, Pro B, Prince HM, et al. Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed peripheral T-cell lymphoma (PTCL) following prior systemic therapy. Blood 2010;116(Suppl. 1): Abstract 114.
   Google Scholar
• Piekarz R, Wright J, Frye R, et al. Final results of a phase 2 NCI multicenter study of romidepsin in patients with relapsed peripheral T-cell lymphoma (PTCL). Blood 2009;114(Suppl. 1): Abstract 1657.
   Google Scholar
• Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012;30:2190–2196.
   PubMed Web of Science ®Google Scholar
• Fanale MA, Shustov AR, Forero-Torres A, et al. Brentuximab vedotin administered concurrently with multi-agent chemotherapy as frontline treatment of ALCL and other CD30-positive mature T-cell and NK-cell lymphomas. Blood 2012;120(Suppl. 1): Abstract 60.
   PubMed Web of Science ®Google Scholar
• A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) alternating with pralatrexate (P) as front line therapy for patients with stage II, III and IV peripheral T-cell non-Hodgkin lymphoma (NCT01336933). Available from: www.ClinicalTrials.gov
   Google Scholar
• A study of escalating doses of romidepsin in association with CHOP in the treatment of peripheral T-cell lymphomas (NCT01280526). Available from: www.ClinicalTrials.gov
   Google Scholar
• Brentuximab vedotin and bendamustine for the treatment of Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL) (NCT01657331). Available from: www.ClinicalTrials.gov
   Google Scholar
• Dupuis J, Casasnovas RO, Morschhauser F, et al. Early results of a phase Ib/II dose-escalation trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphomas (PTCL). Blood 2011;118(Suppl. 1): Abstract 2673.
   Google Scholar
• Study of pralatrexate versus observation following CHOP-based chemotherapy in previously undiagnosed peripheral T-cell lymphoma patients (NCT01420679). Available from: www.ClinicalTrials.gov
   Google Scholar